CTIS2023-505917-25-00进行中（未招募）1 期
eoadjuvant pembrolizumab plus chemotherapy in locally advanced sinonasal carcinoma (NeoPeSino) - NeoPeSino
Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb0 个研究点目标入组 28 人开始时间: 2023年7月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1.Have centrally histologically-confirmed, treatment-naïve SNUC that is considered curable by local therapies. Resectability at diagnosis should be recorded on the electronic case report form (eCRF) but is not a required inclusion criteria. 2.Have locally advanced disease defined as stage III of IVa-b according to AJCC cancer staging system VIII edition. 3.Be willing and able to provide written informed consent for the trial. The subject may also provide consent for Future Biomedical Research. However, the subject may participate in the main trial without participating in Future Biomedical Research. 4.Be = 18 years of age on day of signing informed consent. 5.Have measurable disease based on RECIST 1.1 as determined by the site. 6.Have a performance status of 0 or 1 on the ECOG Performance Scale. 7.Demonstrate adequate organ function as defined in Table 4, all screening labs should be performed within 15 days of treatment initiation. 8.A male participant must agree to use a contraception as detailed in Appendix 3 of this protocol during the treatment period and for at least 180 days, corresponding to time needed to eliminate any study treatments plus an additional 90 days (a spermatogenesis cycle) for study treatments with evidence of genotoxicity at any dose after the last dose of study treatment and refrain from donating sperm during this period. 9.A female participant is eligible to participate if she is not pregnant (see Appendix 3), not breastfeeding, and at least one of the following conditions applies: a.Not a woman of childbearing potential (WOCBP) as defined in Appendix 3 OR b.A WOCBP who agrees to follow the contraceptive guidance in Appendix 3 during the treatment period and for at least 180 days (corresponding to time needed to eliminate any study treatments plus 30 days (a menstruation cycle) for study treatments with risk of genotoxicity after the last dose of study treatment.. 10.Have provided tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides. Newly obtained biopsies are preferred., 2.Have locally advanced disease defined as stage III of IVa-b according to AJCC cancer staging system VIII edition., 5. Have measurable disease based on RECIST 1.1 as determined by the site., 6.Have a performance status of 0 or 1 on the ECOG Performance Scale.
排除标准
- •1.Has disease that is deemed not suitable for local therapy administered with curative intent (e.g. severe brain involvement)., 2.Have metastatic disease defined as stage IVc according to AJCC cancer staging system VIII edition., 4.Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX 40, CD137)., 5.Has received prior systemic anti-cancer therapy including investigational agents prior to allocation.
研究者
相似试验
进行中（未招募）
1 期
Immunotherapy and chemotherapy treatment or no treatment guided by the level of tumour-infiltrating cells in resected early-stage triple-negative breast cancer (i.e. without hormone receptor or HER2 protein receptor)Triple negative breast cancerMedDRA version: 20.0Level: PTClassification code: 10006187Term: Breast cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10006199Term: Breast cancer stage I Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10075566Term: Triple negative breast cancer Class: 100000004864CTIS2023-504620-26-00nicancer364
招募中
2 期
Pembrolizumab in Locally Advanced Sinonasal CarcinomaSinonasal Undifferentiated CarcinomaNCT05925491Istituti Clinici Scientifici Maugeri SpA28
进行中（未招募）
2 期
A study to examine the effects of preoperative envafolimab and chemotherapy in advanced stomach and gastroesophageal junction cancerCancerISRCTN14298588West China Hospital of Sichuan University35
招募中
2 期
eo-adjuvant Pembrolizumab as an alternative treatment for MMRd uterine cancer, a phase II efficacy studyNL-OMON53535niversitair Medisch Centrum Groningen12
尚未招募
不适用
Pembrolizumab with standard cytotoxic chemotherapy in treatment naive non-small cell lung cancer patients with asymptomatic brain metastasesNeoplasmsKCT0006563Samsung Medical Center50